NCT01381341 To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib. Status COMPLETED Phase PHASE1
NCT01363232 Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients Status COMPLETED Phase PHASE1
NCT01352273 MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations Status COMPLETED Phase PHASE1
NCT01340547 Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors Status UNKNOWN Phase PHASE1
NCT01331941 A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function Status COMPLETED Phase PHASE1
NCT01327612 Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) Status COMPLETED Phase PHASE2
NCT01306630 A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT01302405 Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors Status TERMINATED Phase PHASE1
NCT01299701 A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors Status TERMINATED Phase PHASE1
NCT01296581 Safety Study of X-82 in Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT01293630 A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT01286974 A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors. Status TERMINATED Phase PHASE1
NCT01255657 A Study of ABT-806 in Subjects With Advanced Solid Tumor Types Status COMPLETED Phase PHASE1
NCT01248949 A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT01238952 Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer Status COMPLETED Phase PHASE1
NCT01238939 Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer Status COMPLETED Phase PHASE1
NCT01235897 MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies Status COMPLETED Phase PHASE1